<DOC>
	<DOCNO>NCT03098979</DOCNO>
	<brief_summary>The objective study find optimal dose daily oral neladenoson bialanate ( BAY1067197 ) give addition appropriate therapy specific comorbidities .</brief_summary>
	<brief_title>A Trial Study Neladenoson Bialanate Over 20 Weeks Patients With Chronic Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adenosine A1 Receptor Agonists</mesh_term>
	<criteria>Men woman age 45 year old Diagnosis chronic heart failure , NYHA ( New York Heart Association ) class IIIV , LVEF ( leave ventricular ejection fraction ) â‰¥ 45 % elevate NTproBNP Acute decompensated heart failure within past 4 week Inability exercise Previous diagnosis HFrEF ( heart failure reduce ejection fraction ) ( LVEF &lt; 40 % )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Heart Failure Preserved Ejection Fraction</keyword>
</DOC>